Stock Code: Sunflower Pharmaceutical Group Co.Ltd(002737) stock abbreviation: Sunflower Pharmaceutical Group Co.Ltd(002737) Announcement No.: 2022005 Sunflower Pharmaceutical Group Co.Ltd(002737)
Announcement of resolutions of the 14th meeting of the 4th board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Sunflower Pharmaceutical Group Co.Ltd(002737) (hereinafter referred to as “the company” or “the company”) the 14th meeting of the 4th board of directors was held by means of communication at 9 a.m. on March 3, 2022. The meeting notice and proposal were sent out by email on February 28, 2022. There are 9 directors who should vote at the meeting and 9 directors who actually vote. The convening, convening procedures and attendance of this meeting comply with the provisions of the company law, relevant laws and regulations and the articles of association, and the meeting is legal and effective.
The meeting was convened by Ms. Guan Yuxiu, the chairman of the board of directors, and the following resolutions were adopted by communication voting of the directors attending the meeting:
1、 Deliberated and passed the proposal on appointing the person in charge of internal audit
In view of the resignation of Mr. Liu Baodong, the former person in charge of internal audit of the company, in order to ensure the standardized operation of the company and the quality of internal audit business, it is agreed to appoint Mr. Li Jinming, deputy general manager, as the person in charge of internal audit of the company until the expiration of this board of directors.
For details, please refer to securities times, China Securities News and cninfo.com.cn, the designated information disclosure media of the company.
Voting results: 9 in favor, 0 against and 0 abstention, passed.
2、 Deliberated and passed the proposal on by election of independent directors of the company
Since Mr. Li Huajie, the independent director, has resigned from the relevant positions of the independent director of the company and the special committees under the board of directors, he agrees to nominate Mr. Shi Xianwang as the candidate for independent director of the Fourth Board of directors of the company, and the term of office starts from the date of deliberation and approval of the general meeting of shareholders to the date of expiration of the current board of directors.
The independent directors of the company have expressed their independent opinions on this matter. For independent opinions, please refer to securities times, China Securities News and cninfo (www.cn. Info. Com. CN), the designated information disclosure media of the company. Voting results: 9 in favor, 0 against and 0 abstention, passed.
This proposal shall be submitted to the general meeting of shareholders of the company for deliberation.
3、 The proposal on convening the first extraordinary general meeting of shareholders in 2022 was deliberated and adopted
It is agreed that the board of directors of the company will convene the first extraordinary general meeting of shareholders in 2022. See the specific announcement for the details of the meeting.
The notice and announcement of the general meeting of shareholders of the company are disclosed in the securities times, China Securities News and cninfo (www.cn. Info. Com. CN), the designated information disclosure media of the company.
Voting results: 9 in favor, 0 against and 0 abstention, passed.
Documents for future reference:
1. Resolution of the 14th meeting of the 4th board of directors of the company
2. Independent opinions of independent directors
It is hereby announced.
Sunflower Pharmaceutical Group Co.Ltd(002737) board of directors
March 3, 2022
